Contrasting Kyntra Bio (NASDAQ:KYNB) & Immatics (NASDAQ:IMTX)

Kyntra Bio (NASDAQ:KYNB) and Immatics (NASDAQ:IMTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.

Earnings & Valuation

This table compares Kyntra Bio and Immatics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44 million	3.37	$183.45 million	$45.30	0.12
Immatics	$54.60 million	17.87	-$222.26 million	($1.86)	-3.84

Kyntra Bio has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kyntra Bio and Immatics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Immatics	-495.71%	-47.41%	-39.45%

Institutional and Insider Ownership

72.7% of Kyntra Bio shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by company insiders. Comparatively, 3.3% of Immatics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Kyntra Bio and Immatics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	2	0	5	0	2.43
Immatics	1	0	7	0	2.75

Kyntra Bio presently has a consensus price target of $36.80, indicating a potential upside of 586.57%. Immatics has a consensus price target of $19.67, indicating a potential upside of 175.44%. Given Kyntra Bio’s higher probable upside, analysts plainly believe Kyntra Bio is more favorable than Immatics.

Volatility & Risk

Kyntra Bio has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Immatics has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.

Summary

Kyntra Bio beats Immatics on 7 of the 13 factors compared between the two stocks.

About Kyntra Bio

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.